Charles River Laboratories International Inc. (CRL) News

Charles River Laboratories International Inc. (CRL): $219.00

2.48 (-1.12%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Filter CRL News Items

CRL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CRL News Highlights

  • For CRL, its 30 day story count is now at 9.
  • Over the past 22 days, the trend for CRL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about CRL are AGE and EYE.

Latest CRL News From Around the Web

Below are the latest news stories about CHARLES RIVER LABORATORIES INTERNATIONAL INC that investors may wish to consider to help them evaluate CRL as an investment opportunity.

What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?

Charles River Laboratories International, Inc. ( NYSE:CRL ) led the NYSE gainers with a relatively large price hike in...

Yahoo | December 27, 2023

Charles River's (CRL) Memphis Site Achieves Crucial Approval

Charles River (CRL) reaches an important milestone in cell therapy manufacturing collaboration with Vertex Pharmaceuticals.

Yahoo | December 19, 2023

Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration

WILMINGTON, Mass. & MEMPHIS, Tenn., December 18, 2023--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important milestone in their strategic collaboration to manufacture CASGEVY™ (exagamglogene autotemcel [exa-cel]). CASGEVY is approved in some countries for certain eligible patients.

Yahoo | December 18, 2023

Charles River (CRL) Expands 3D In Vitro Services Via New Deal

Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.

Yahoo | December 13, 2023

Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening

WILMINGTON, Mass. & BERLIN, December 12, 2023--Charles River expands portfolio of 3D in vitro testing services for oncology research with CELLphenomics' proprietary PD3D tumor model platform.

Yahoo | December 12, 2023

Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Yahoo | December 11, 2023

Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue?

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Investing in the Aging Population: 3 Healthcare Stocks to Watch

America is becoming a much older country on average.

Ian Bezek on InvestorPlace | December 7, 2023

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.

Yahoo | December 5, 2023

Insider Sell: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)

Joseph Laplume, the Executive Vice President of Corporate Strategy & Development at Charles River Laboratories International Inc (NYSE:CRL), has recently sold 1,850 shares of the company's stock.

Yahoo | December 2, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!